TherapeuticsMD, Inc. - FORM 10-K - EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - March 3, 2021

Attached files

file filename
10-K - ANNUAL REPORT - TherapeuticsMD, Inc.txmd-10k_123120.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - TherapeuticsMD, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex31-1.htm
EX-23.1 - CONSENT OF GRANT THORNTON LLP - TherapeuticsMD, Inc.ex23-1.htm
EX-10.42 - AMENDMENT TO EMPLOYMENT AGREEMENT WITH EDWARD J. BORKOWSKI - TherapeuticsMD, Inc.ex10-42.htm
EX-10.41 - EMPLOYMENT AGREEMENT WITH EDWARD J. BORKOWSKI - TherapeuticsMD, Inc.ex10-41.htm
EX-10.25 - AMENDMENT NO. 8 TO THE FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-25.htm
EX-10.24 - AMENDMENT NO. 7 TO THE FINANCING AGREEMENT - TherapeuticsMD, Inc.ex10-24.htm
EX-10.16 - AMENDMENT TO WARRANT ISSUED TO JOHN C.K. MILLIGAN, IV - TherapeuticsMD, Inc.ex10-16.htm
EX-10.15 - WARRANT ISSUED TO JOHN C.K. MILLIGAN, IV - TherapeuticsMD, Inc.ex10-15.htm
EX-10.14 - AMENDMENT TO WARRANT ISSUED TO ROBERT G. FINIZIO - TherapeuticsMD, Inc.ex10-14.htm
EX-10.13 - WARRANT ISSUED TO ROBERT G. FINIZIO - TherapeuticsMD, Inc.ex10-13.htm
EX-10.12 - SECOND AMENDMENT TO COMPANY WARRANT - TherapeuticsMD, Inc.ex10-12.htm

 

TherapeuticsMD, Inc. 10-K

 

Exhibit 32.2

 

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

In connection with the annual report of TherapeuticsMD, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James C. D’Arecca, Chief Financial Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(3)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

 

(4)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 3, 2021

 

  /s/ James C. D’Arecca
  James C. D’Arecca
  Chief Financial Officer
  (Principal Financial Officer)

 

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 86

TherapeuticsMD, Inc. Reports